Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
ANI Pharmaceuticals
NasdaqGM:ANIP Community
1
Narratives
written by author
0
Comments
on narratives written by author
2
Fair Values set
on narratives written by author
Create a narrative
ANI Pharmaceuticals
Popular
Undervalued
Overvalued
ANI Pharmaceuticals
WA
Analyst Price Target
Consensus Narrative from 6 Analysts
New Clinical Trials Will Expand ILUVIEN And YUTIQ Market Presence In 2025
Key Takeaways Successful Alimera acquisition integration is set to enhance financial metrics and drive notable EPS growth. Cortrophin Gel's growth, driven by new developments and market expansion, is poised to significantly boost revenue in coming years.
View narrative
US$78.67
FV
25.2% undervalued
intrinsic discount
13.01%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 1 month ago
author updated this narrative
Your Valuation for
ANIP
ANI Pharmaceuticals
Your Fair Value
US$
Current Price
US$58.81
29.2% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-50m
890m
2015
2018
2021
2024
2025
2027
2030
Revenue US$890.2m
Earnings US$130.6m
Advanced
Set as Fair Value